Literature DB >> 12814814

Oral and vaginal misoprostol 800 microg every 8 h for early abortion.

J L L Carbonell1, J Rodríguez, A Velazco, R Tanda, C Sánchez, S Barambio, S Chami, F Valero, J Marí, F de Vargas, I Salvador.   

Abstract

The objective of the study was to evaluate the efficacy and safety of 800 microg misoprostol (Cytotec) every 8 h for 24 h for pharmacological abortion; the treatment was repeated if abortion did not occur in the first 24-h interval. The first misoprostol doses were always self-administered into the vagina; the second and third doses could be administered orally or vaginally depending on the amount of bleeding. Four-hundred and fifty-two women with gestations between 36 and 63 days were recruited into the study. The main outcomes assessed were: successful abortion (complete abortion without surgery), side effects, mean drop in hemoglobin, vaginal bleeding and mean time of return of menstruation. Complete abortion occurred in 409/452 (90.5%; 95% confidence interval [CI] 87%, 93%) patients. Medication to relieve symptoms was administered to all women before the first misoprostol dose. Vaginal bleeding lasted 15.9 +/- 4.4 days. The mean drop in hemoglobin, measured 14 days after abortion, was statistically significant (p = 0.0001) but without clinical relevance. According to the results obtained, 800 microg of misoprostol administered every 8 h for 24 h could be a valid method for abortion for up to 9 weeks of gestation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12814814     DOI: 10.1016/s0010-7824(03)00043-x

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  2 in total

1.  Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review.

Authors:  Elizabeth G Raymond; Margo S Harrison; Mark A Weaver
Journal:  Obstet Gynecol       Date:  2019-01       Impact factor: 7.661

2.  Women's experiences using drugs to induce abortion acquired in the informal sector in Colombia: qualitative interviews with users in Bogotá and the Coffee Axis.

Authors:  Ann M Moore; Juliette Ortiz; Nakeisha Blades; Hannah Whitehead; Cristina Villarreal
Journal:  Sex Reprod Health Matters       Date:  2021-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.